Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining.
Calliditas Therapeutics Earlier Reported Q2 EPS $(0.38) Beats $(0.48) Estimate
Calliditas Therapeutics (NASDAQ:CALT) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.48) by 20.83 percent. This is a 153.33 percent decrease over losses of $(0.15) per
Earnings Scheduled For August 19, 2021
Companies Reporting Before The Bell
• Bilibili (NASDAQ:BILI) is likely to report quarterly loss at $2.86 per share on revenue of $658.78 million.
66 Biggest Movers From Yesterday
Gainers
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019.
48 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares jumped 93% to $$8.10 after the company received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019.
25 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
Cardiol Therapeutics Inc. (NASDAQ: CRDL) shares rose 25.8% to $3.27 in pre-market trading after dropping around 7% on Monday.